Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 67%
Buy 27%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is positioned favorably in the mental health care market due to its innovative approach to psilocybin therapy for treatment-resistant depression, as demonstrated by its proprietary formulation, COMP360, which shows superior efficacy compared to existing therapies like Spravato. The company’s promising phase 2b data indicates the potential for substantial market success, particularly with estimates suggesting a significant commercial opportunity driven by broader momentum in psychedelic treatments and supportive government initiatives for mental health. Furthermore, the anticipated durability of therapeutic response, coupled with reduced inpatient treatment experiences, enhances the attractiveness of COMP360 as a viable treatment option, indicating strong potential for revenue growth.

Bears say

Compass Pathways PLC is subject to significant risk regarding the potential failure of its COMP360 psilocybin therapy and other pipeline programs in clinical trials, which could negatively impact stock performance. The recent adverse outcomes associated with Lykos Therapeutics—including a negative advisory committee vote and a Complete Response Letter (CRL)—suggest a heightened scrutiny from regulatory bodies that may affect broader acceptance and approval of psychedelic therapies, including those proposed by Compass Pathways. Additionally, sustained response rates reported for competing therapies indicate that achieving clinically meaningful efficacy may be increasingly challenging, further complicating Compass Pathways's positioning in the market.

COMPASS Pathways (CMPS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 27% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.